Compare · ONCR vs VLON

ONCR vs VLON

Side-by-side comparison of Oncorus Inc. (ONCR) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ONCR and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • VLON has more recent analyst coverage (1 ratings vs 0 for ONCR).
MetricONCRVLON
Company
Oncorus Inc.
Vallon Pharmaceuticals Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2020
2021
News (4w)
0
0
Recent ratings
0
1
ONCR

Oncorus Inc.

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VLON

Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Latest ONCR

Latest VLON